palmitoylethanolamide.com.au
HomeResearchUdovin 2020

Partial Reversal of Striatal Damage by Palmitoylethanolamide Administration Following Perinatal Asphyxia

Udovin LD, Kobiec T, Herrera MI, Toro-Urrego N, Kusnier CF, Kolliker-Frers RA, Ramos-Hryb AB, Luaces JP, Otero-Losada M, Capani F. Front Neurosci. 2020 Jan 8;13:1345.

Laboratory studyOther animals

Design
Laboratory study
Subjects
Newborn rat pups subjected to a perinatal asphyxia model (Bjelke method), then followed for 30 days
Dose used in the study
PEA, 10 mg/kg, subcutaneous, given one hour after asphyxia
Duration
30 days
What was measured
Striatal neuron markers (phosphorylated neurofilament pNF-H/M, MAP-2) and astrocyte marker GFAP, by western blot and immunohistochemistry.

What the authors reported

Perinatal asphyxia reduced pNF-H/M and MAP-2 reactive areas and protein expression, and reduced GFAP-positive cell numbers, without changing total GFAP protein. PEA treatment largely restored GFAP-positive cell numbers, improved the reduction in pNF-H/M and MAP-2 reactive areas, reversed the fall in MAP-2 and largely prevented the fall in pNF-H/M protein expression.

Limits of this study

A neonatal rat model of asphyxia; it cannot show effect in infants. Funding and conflicts not stated in the abstract.

Source

PubMed 31969800 · doi:10.3389/fnins.2019.01345

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.